About Beta-enolase
Beta-enolase (ENO3) is a protein
from Homo sapiens identified by UniProt accession
P13929, 434 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Beta-enolase |
| UniProt accession | P13929 |
| Gene | ENO3 |
| Organism | Homo sapiens |
| Length | 434 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (94)
Diseases linked to this target (Open Targets).
- glycogen storage disease due to muscle beta-enolase deficiency · score 0.72
- disorder of glycogen metabolism · score 0.49
- neurodegenerative disease · score 0.48
- Red cell distribution width · score 0.20
- mean platelet volume · score 0.20
- platelet count · score 0.20
- genetic disorder · score 0.19
- amyotrophic lateral sclerosis · score 0.15
- type 2 diabetes mellitus · score 0.11
- intraocular pressure measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P13929-F1 | alphafold | PREDICTED | 97.56 | — |
Amino-acid sequence (434 residues)
MAMQKIFARE ILDSRGNPTV EVDLHTAKGR FRAAVPSGAS TGIYEALELR DGDKGRYLGK GVLKAVENIN NTLGPALLQK KLSVVDQEKV DKFMIELDGT ENKSKFGANA ILGVSLAVCK AGAAEKGVPL YRHIADLAGN PDLILPVPAF NVINGGSHAG NKLAMQEFMI LPVGASSFKE AMRIGAEVYH HLKGVIKAKY GKDATNVGDE GGFAPNILEN NEALELLKTA IQAAGYPDKV VIGMDVAASE FYRNGKYDLD FKSPDDPARH ITGEKLGELY KSFIKNYPVV SIEDPFDQDD WATWTSFLSG VNIQIVGDDL TVTNPKRIAQ AVEKKACNCL LLKVNQIGSV TESIQACKLA QSNGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR SERLAKYNQL MRIEEALGDK AIFAGRKFRN PKAK
Explore Beta-enolase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets